Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p104 | (1) | ICCBH2017

Dietary calcium deficiency contributes to the causation of nutritional rickets (NR) in the United Kingdom (UK): data from the British Paediatric Surveillance Unit (BPSU) NR survey

Zulf Mughal M. , Calder Alistair , Blair Mitch , Julies Priscilla , Pall Karina , Lynn Richard , McDonnell Ciara , McDevitt Helen , Shaw Nick J.

Background: Rickets is a disorder of the growing child arising from impaired mineralisation of the growth plate and osteoid. The most common cause of NR in the UK is thought to be secondary to vitamin D deficiency [VDD; serum 25-hydroxyvitamin D (25OHD) <25 nmol/l], although in some African & South Asian countries dietary calcium deficiency (DCaD) by itself, or together with VDD is an important cause of NR (Ann Trop Paediatr. 2006;26:1–16). Currently, the data on ...

ba0006lb4 | (1) | ICCBH2017

Serious adverse effects of denosumab in adolescents treated for giant cell tumour of the bone: osteonecrosis of the jaw and rebound hypercalcaemia with acute kidney injury

Uday Suma , Gaston Louie , Grimer Robert , Joffe Jonathan , Hoegler Wolfgang

Introduction: Giant cell tumour of the bone (GCTB) is a benign, locally aggressive tumour whose neoplastic stromal cells express receptor activator of nuclear factor kappa-B ligand (RANKL) and activate its receptor RANK on osteoclast-like giant cells. Denosumab (RANKL inhibitor) is an FDA/EMA approved treatment for GCTB in adults and ‘skeletally mature’ adolescents. Safety concerns include oversuppression of bone remodelling, with risk of osteonecrosis of the jaw [ON...

ba0001pp8 | Clinical case posters | ECTS2013

Phenotypic change in a patient with hypophosphatasia with the onset of renal failure

Cundy Tim , Michigami Toshimi , Tachikawa Kanako , Dray Michael , Collins John

Hypophosphatasia is a recessively inherited disorder with a wide phenotypic manifestation ranging from lethality in neonates to asymptomatic in adults. The severity of the phenotype is largely determined by the nature of the ALPL mutations. We describe a previously asymptomatic adult whose phenotype dramatically changed after he developed renal failure. A 50-year-old man was diagnosed with IgA nephropathy. At age 52 (eGFR 50 ml/min) he suffered his first metatarsal fr...

ba0001pp301 | Muscle, physical activity and bone | ECTS2013

Effect of vitamin D status on muscle function and physical performance among saudi postmenopausal women: a cross-sectional study

Hussein Khulood

Introduction: Vitamin D deficiency is common among elderly subjects and is associated with reduced muscle strength. Although vitamin D deficiency is common among Saudi subjects, knowledge about its role in relation to muscle strength and physical performance is lacking. The objectives of the present study are to determine vitamin D status in a sample of randomly selected healthy postmenopausal Saudi women and to investigate the association between their serum 25(OH)D levels an...

ba0001pp478 | Other diseases of bone and mineral metabolism | ECTS2013

Circulating sclerostin level in patients with ossification of the posterior longitudinal ligament of the spine

Kashii Masafumi , Matsuo Yohei , Sugiura Tsuyoshi , Fujimori Takahito , Nagamoto Yukitaka , Honda Hirotsugu , Kaito Takashi , Iwasaki Motoki , Yoshikawa Hideki

Backgrounds: Ossification of the posterior longitudinal ligament (OPLL) is characterized by pathological ectopic ossification of the posterior longitudinal ligament. Development of OPLL induces compression myelopathy or radiculopathy by spinal stenosis and the loss of spinal flexibility by ankylosing spinal hyperosteosis (ASH). Although the etiology of OPLL has not been fully elucidated, systemic and local bone formation factors may play a role in the pathogenesis of OPLL. The...

ba0003pp337 | Osteoporosis: treatment | ECTS2014

Monitoring of calcium intake and vitamin D saturation in Slovak postmenopausal women

Vanuga Peter , Tomkova Sona , Jackuliak Peter , Killinger Zdenko , Payer Juraj

According various guidelines the basic recommendation in prevention and treatment of postmenopausal osteoporosis (PMO) is adequate intake of calcium (1000– 1300 mg/day) and vitamin D (800–1000 IU/day).Aim: To determine the intake dose of calcium and also the vitamin D saturation in women treated for PMO.Patients and methods: 465 women with PMO, divided into two groups: patients with newly diagnosed osteoporosis (n</em...

ba0003pp365 | Other diseases of bone and mineral metabolism | ECTS2014

Alkaline phosphatase bone isoform B1x: a marker of impaired osteoblastic function in patients with renal osteodystrophy

Haarhaus Mathias , Marie-Claude Monier-Faugere , Magnusson Per , Malluche Hartmut

Renal osteodystrophy encompasses the bone histologic abnormalities seen in patients with chronic kidney disease (CKD). The bone-specific alkaline phosphatase (BALP) isoform B1x is exclusively found in serum of some CKD patients. The aim of this study was to examine the relationship between serum BALP isoforms and histologic abnormalities of bone in patients with CKD on chronic dialysis (CKD-5D).Anterior iliac crest bone samples from 40 CKD-5D patients we...

ba0005p91 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2016

PTH and vitamin D in Inuit and non-Inuit in Greenland

Andersen Stig , Schaebel Louise K. , Heickendorf Lene , Mosekilde Leif , Laurberg Peter

Background: Sun exposure may be limited in Arctic populations and Greenland Inuit have adapted to the Arctic environment. The influence of chronic low vitamin D level on PTH to uphold a normal serum calcium remains to be elucidated.Objective: To describe the association between PTH and factors known to influence PTH-, including vitamin D (25OHD) and calcium, in Arctic populations.Methods: Inuit and non-Inuit in the capital city Nuu...

ba0005p221b | Chondrocytes and cartilage | ECTS2016

Vitamin D supplementation for 12 months in older people prevents bone loss and suppresses parathyroid hormone levels

Aspray Terry J , Francis Roger M , McColl Elaine , Chadwick Thomas , Stamp Elaine , Prentice Ann , Schoenmakers Inez

Background, subjects and methods: Vitamin D insufficiency in older people in the UK is common and may cause secondary hyperparathyroidism and bone loss. In a randomised, double blind intervention trial to optimise “Vitamin D status in Older People’ (VDOP) three oral dosages of vitamin D3 (12 kIU, 24 kIU or 48 kIU/month) were given for 12 months to 375 participants aged over 70 years (ANOVA) adjustment for covariables with results below presented in ascendi...

ba0005p410 | Osteoporosis: treatment | ECTS2016

Can bone turnover markers help to define the duration of bisphosphonate drug holidays?

Statham Louise , Aspray Terry , Abdy Sharon

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...